Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Hum Vaccin Immunother ; 10(5): 1195-203, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24614078

RESUMO

BACKGROUND: Concerns about influenza vaccine effectiveness in older adults and the role of influenza strains encountered earlier in life led to this study. METHODS: Antibody responses against antigens in the 2011-2012 influenza vaccine at 21 days post vaccination were analyzed in 264 individuals aged 50-80 years. At Days 0 and 21, sera were tested for hemagglutination-inhibition titers against these vaccine strains and at Day 0 against a panel of 15 historical seasonal strains.: RESULTS: The proportions of participants with seroprotective titers ≥1:40 to the vaccine strains at Days 0 and 21, respectively, were 37% and 66% for A(H1N1) and 28% and 63% for A(H3N2). An increasing number of responses ≥1:40 against historical strains was associated with seroprotective responses after vaccination among participants with a titer<1:40 at Day 0 for A(H1N1) and A(H3N2) vaccine strains (P<0.01). In multivariable regression analyses among those with Day 0 titer<1:40, after controlling for age, sex, race, site and diabetes, Day 21 titers ≥ 1:40 for the vaccine A strains were significantly more likely as the number of seroprotective responses against historical strains increased (A(H1N1) odds ratio [OR] = 1.41, 95% confidence interval [CI] = 1.09-1.82 and A(H3N2) OR = 1.32, 95% CI = 1.07-1.62). The likelihood of seroconversion was significantly higher with an increasing number of responses to historical strains for A(H3N2) only (OR = 1.24, 95% CI = 1.01-1.52). Seroconversion was significantly less likely as Day 0 vaccine strain titers increased. CONCLUSIONS: Seroprotective titers after influenza vaccination increased as the number of responses to historical strains increased.


Assuntos
Anticorpos Antivirais/imunologia , Hemaglutinação/imunologia , Vírus da Influenza A Subtipo H3N2/imunologia , Vacinas contra Influenza/imunologia , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Formação de Anticorpos/efeitos dos fármacos , Formação de Anticorpos/imunologia , Feminino , Hemaglutinação/efeitos dos fármacos , Testes de Inibição da Hemaglutinação/métodos , Humanos , Vírus da Influenza A Subtipo H3N2/efeitos dos fármacos , Vacinas contra Influenza/administração & dosagem , Masculino , Pessoa de Meia-Idade , Vacinas de Produtos Inativados/administração & dosagem , Vacinas de Produtos Inativados/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...